Publication | Open Access

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer

VaccinationUrologyGenitourinary CancerImmunologyTherapeutic VaccineProstate Cancer VaccinePrecision VaccineTf ClusterVaccine DesignImmunotherapyMedicineProstatic Disease